Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
45 results about "Neurturin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Neurturin (NRTN) is a protein. Neurturin belongs to the glial cell-line derived neurotrophic factor (GDNF) family of neurotrophic factors, which regulate the survival and function of neurons. Neurturin’s role as a growth factor places it in the TGF-beta (transforming growth factor) subfamily along with its homologs persephin, artemin, and GDNF. It is also considered a trophic factor and critical in the development and growth of neurons in the brain. Neurotrophic factors like neurturin have been tested in several clinical trial setting for the potential treatment of neurodegenerative diseases, specifically Parkinsons Disease.
In vivo gene therapy of parkinson's disease
InactiveUS20060239966A1Good treatment effectEasy treatmentBiocideNervous disorderIn vivoMammalian cell
The present invention concerns methods and compositions for gene therapy, in particular in vivo gene therapy for delivery of bioactive Neurturin for the treatment of Parkinson's Disease. In another aspect the invention relates to virus expression constructs comprising a mammalian signal peptide linked to a mature or N-terminally truncated Neurturin without a functional pro-region between the signal peptide and the Neurturin. These viral expression constructs are required for efficient secretion of bioactive Neurturin in in vivo gene therapy. The invention also concerns mammalian cells capable of producing Neurturin in increased amounts as well as the use of these cells for recombinant production of bioactive Neurturin and for therapeutic use.
Owner:CEREGENE
Neurotrophin production secretion promoting agent
InactiveUS6605629B1Excellent neurotrophin production/secretion promoting activityHigh activityBiocideNervous disorderAcyl groupNeurotrophin production
A neurotrophin production / secretion promoting agent which comprises an azole derivative of the formula:wherein R1 represents a halogen atom, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, a thiol group which may optionally be substituted, or an amino group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, or a carboxyl group which may optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; X represents oxygen atom, sulfur atom, or nitrogen atom which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof; which is useful as an agent for preventing or treating neuropathy.
Owner:TAKEDA PHARMA CO LTD
Neurturin receptor
InactiveUS6777196B2Cell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsExtracellularCell activity
NTNRalpha, NTNRalpha extracellular domain (ECD), NTNRalpha variants, chimeric NTNRalpha (e.g., NTNRalpha immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNRalpha-ligands, for example NTN, by providing NTNRalpha to the cell.
Owner:GENENTECH INC
Treatment of Metabolic-Related Disorders Using Hypothalamic Gene Transfer of BDNF and Compositions Therefor
ActiveUS20110288160A1Reduces neuronal excitabilityRelieve symptomsVectorsMetabolism disorderDiseaseGene transfer
Described herein is a system which uses a gene therapy particle that includes at least one gene, cDNA, fragment or analogue of at least one neurotropin that binds to the trkB receptor or the trkB receptor itself. The gene therapy particle is capable of being delivered to a subject in need thereof for therapy of a metabolic disorder. In a particular aspect, this invention is directed to an inventive method that demonstrates a remarkable efficacy on lowering body weight.
Owner:THE OHIO STATES UNIV
Novel neurturin conjugates for pharmaceutical use
InactiveUS20110003741A1Improve bioavailabilityProlong lifeNervous disorderNeuregulinsPolyolBULK ACTIVE INGREDIENT
The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
Owner:EVOTEC INTERNATIONAL GMBH
Method for Preventing and Treating Diabetes Using Neurturin
InactiveUS20080241106A1Reduce the numberReduce in quantityBiocidePeptide/protein ingredientsDiseaseDiabetes mellitus
Owner:DEVELOGEN AKTIENGES
Use of protocatechuic acid in accelerating nerve stem cell multiplication in vitro and inducement differentiation
InactiveCN101104845APromotes significant proliferationKeep proliferatingNervous disorderUnknown materialsIntellectual propertyProviding material
The invention belonging to the cell biology and pharmacology technical field relates to the purpose of a Chinese traditional medicine monomeric compound, in particularly to the new purpose of a protocatechuic acid in the aspect of promoting the external proliferation and induction-differentiation of a nerve stem cell. The invention is characterized in the application of producing medicine to treat the neurodegenerative diseases by nerve stem cell transplantation, in the application of producing neurenergen and cell differential agent for restoring damaged nerve tissues and reconstructing nerve functions, and in the application of constructing high efficient medical screening model to initially screen and appraise the efficacy of medicine. The invention confirms the new phamacoloic activity of the protocatechuic acid, providing material basis with regard to prevention effect of the Chinese traditional medicine, and providing reference for the development of new medicine with independent intellectual property rights.
Owner:DALIAN UNIV OF TECH
Nerve regeneration gel as well as preparation method and application thereof
ActiveCN107970438AAvoid Oxidative DamageInhibitory reactivityOrganic active ingredientsNervous disorderNervous systemCuticle
The invention discloses a nerve regeneration gel as well as a preparation method and application thereof. The matrix of the nerve regeneration gel is formed by fibrinogen, thrombin, laminin and fibronectin; the nerve regeneration gel contains procyanidine, sonic hedgehog, an epidermal growth factor, neurenergen-3 and a vascular endothelial growth factor. In-vitro test and animal test show that thegel is capable of accelerating neuron regeneration and neurite extension and repairing the injured nerve tissue. The matrix of the gel comprises fibrin, laminin and fibronectin and is capable of reducing formation of cavities and accelerating adhesion and proliferation of endogenous neural stem cells; the procyanidine in the gel is capable of resisting oxidation and inhibiting inflammation; the sonic hedgehog, the epidermal growth factor and the neurenergen-3 are capable of accelerating proliferation of the stem cells and differentiation to neurons of the stem cells; the vascular endothelialgrowth factor is capable of accelerating generation of blood vessels. The gel can be formed in situ on injured parts and can be used for treating nervous system injury.
Owner:镇江市中西医结合医院
Method of cell culture using neurturin
InactiveUS6743628B1Peptide/protein ingredientsGenetic material ingredientsNeurotrophic factorsGenomic DNA
A novel growth factor, neurturin, is disclosed. The human and mouse amino acid sequences have been identified. Human and mouse neurturin genomic DNA sequences have been cloned and sequences and the respective CDNA sequences identified. The subcloning into vectors and the preparation of cells stably transformed with the vectors is also disclosed. In addition, methods for treating degenerative conditions using neurturin, methods for detecting gene alterations and methods for detecting and monitoring patient levels of neurturin are provided. Methods for identifying additional members of the neurturin-GDNF family of growth factors are also provided.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Method for constructing human neurenergen-3 receptor gene recombination adenovirus
InactiveCN1683541AExtend your lifeImprove the quality of lifeMicrobiological testing/measurementGenetic engineeringShuttle vectorCentral neuron
The present invention relates to the construction method and application of one kind of human neurenergen-3 receptor gene (human TrkC gene) recombined adenovirus expressing vector. The basic scheme of the present invention includes: designing and synthesizing primer, RT-PCR process, construction and identification of cloned shuttle vector pShuttle-TrkC, construction and identification of recombined adenovirus vector pAdeno-TrkC, 293 cell packaging, identification of recombined adenovirus, bioactivity detection of human neurenergen-3 receptor gene recombined adenovirus expressing vector and other steps. The present invention is superior in that one kind gene recombined adenovirus expressing vector is selected to promote the survival of damaged central neure and the regeneration of axone, to promote nerve stem cell to differentiate into more neures to replace damaged or dead neures.
Owner:SUN YAT SEN UNIV
Biomarker metabolic pathway, and analysis method and application
The invention belongs to the technical field of functional analysis methods of disease metabolism biomarkers, and provides a biomarker metabolic pathway and an analysis method. The metabolic biomarker is stearic acid, phytosphingosine, glycine, glutamine and phospholipids; an acting target spot of the metabolic biomarker is a target protein related to a depression nervous system, immune response and endocrine; and the metabolic pathway is a PI3K-Akt signaling pathway, an mTOR signaling pathway, an MAPK signaling pathway, an erbB signaling pathway, a neurenergen signaling pathway, an Rap1 signaling pathway and an Ras signaling pathway. A functional network analysis method suitable for depression characteristics is established, and the clinical application of these biomarkers helps to optimize the diagnosis of depression, and can provide some valuable clues for the subsequent depression network function researches.
Owner:SHANXI UNIV
Application of naringin in promoting proliferation and differentiation of neural stem cell
ActiveCN103060271AKeep proliferatingContribute to further developmentOrganic active ingredientsNervous disorderNaringinIntellectual property
The invention belongs to the field of regenerative medicine and pharmacology, relates to an application of a double hydrogen flavonoid small molecule compound, and particularly relates to a new application of naringin in promoting proliferation and differentiation of a neural stem cell. The invention is characterized by relating to an application of the naringin in medicament for neural stem cell transplantation in the treatment of neurodegenerative diseases, an application of the naringin in repairing damaged nerve tissues and preparation a function-reconstructable nerve nutriment and cell differentiation agent, and an application of the naringin in constructing an efficient medicament screening model and applying the efficient medicament screening model to preliminary screening and evaluation of the medicament efficacy. The invention confirms the new pharmacological activity of the naringin, establishes an application foundation in stem cell transplantation (SCT), and provides new thoughts for developing new medicaments with independent intellectual property rights.
Owner:北京清美联创干细胞科技有限公司
Method for preparing tissue engineering spinal cords by using mesenchymal stem cells derived from dermis
The invention discloses a method for preparing tissue engineering spinal cords by using mesenchymal stem cells derived from dermis, which comprises the following steps of 1) separating dMSCs, and carrying out passage on the dMSCs so as to obtain dMSCs primary cells; 2) moving the dMSCs primary cells obtained through separating to an amplification culture medium so as to carry out amplification; and 3) dropwise adding an engineering spinal cord saturated water solution into a physiological saline solution containing deep nerve nutriments, retinoic acid and Neuregulin, standing the obtained mixture, carrying out gradient alcohol dehydration on the mixture, and carrying out vacuum drying on the mixture; and infecting the dMSCs subjected to amplification by using a brain-derived neurenergen adenovirus expression vector, and inoculating cells to an engineering spinal cord material for culturing. In the method, tissue engineering spinal cords can effectively promote cell proliferation; and the differentiation rates of the tissue engineering spinal cords to nerve cells and oligodendroglia cells are respectively about 4.8% and 1.5% which are far higher than those of pure scaffold materials (the differentiation rates of pure scaffold materials to nerve cells and oligodendroglia cells are respectively 1.8% and 0.5%).
Owner:ARMY MEDICAL UNIV
New formulation for increasing bioavailability of neurturin
InactiveUS20090258829A1Organic active ingredientsNervous disorderNeurotrophic factorsBioavailability
The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability.
Owner:DEVELOGEN AKTIENGES
Applications human neuro nutriment-3 receptor gene recombination ad virus for preparing medicine treating nerve injury
InactiveCN101254310AExtend your lifeImprove the quality of lifeNervous disorderGenetic material ingredientsCentral neuronNeurotrophin-3
The invention relates to a biological activity of an adenovirus expression vector which is recombined by using a human neurotrophin-3 receptor gene (human TrkC gene) and an application in the nerve injury repair thereof. The human Ad-TrkC can be used for promoting the survival of the injured central neurons and the axonal regeneration, so as to promote the neural stem cells to be more divided into the neurons with the potential of synaptic formation, further to replace the injured neurons or the dead neurons. The biological activity strengthens the protection mechanism of the central nervous system after the injury on the gene treatment level, replaces the injured neurons, participates in the reconstruction of the neural network and repairs the functions of the central nervous. Thus, the application has important significances for prolonging the human life, improving the quality of lives of the wounds and the patients, reducing the social and the family burdens and promoting the development of Chinese socioeconomic development.
Owner:SUN YAT SEN UNIV
Crystalline forms of neurotrophin mimetic compounds and their salts
Owner:PHARMATROPHIX
Agonists of Neurotrophin Receptors and Their Use as Medicaments
ActiveUS20120052094A1Preventing and treating nerve cell deathPreventing and treating and damageOrganic active ingredientsSenses disorderNeurotrophin Receptor p75Medicine
The invention relates to compounds of Formula I:and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS CSIC UNDIVIDED 20 INTEREST +1
Use of protocatechuic acid in accelerating nerve stem cell multiplication in vitro and inducement differentiation
InactiveCN100560718CPromotes significant proliferationKeep proliferatingNervous disorderUnknown materialsIntellectual propertyProviding material
Owner:DALIAN UNIV OF TECH
Method for preventing and treating diabetes using neurturin
Owner:EVOTECH INT GMBH
Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
ActiveUS9265843B2Enhanced signalReduce excitabilityVectorsMetabolism disorderGene transferBody weight
Owner:THE OHIO STATES UNIV
Pharmaceutical compositions for the treatment of diseases related to neurotrophines
The present invention refers to pharmaceutical preparations including as active compounds 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I) and / or their dimers of general formula (II) and (III) acting as agonists of human neurotrophines. Therefore, such compounds of formula (I), (II) and (III) are useful for treatment of diseases in which the neurotrophine functions are involved in defect, particularly of Nerve Growth Factor (NGF), such as neurodegenerative diseases of central nervous system (CNS), acquired immunodeficiency due to a reduced NGF biodisponibility, or morbous conditions in which the stimulus of neoangiogenesis process is convenient.
Owner:MIMETECH
Agonists of neurotrophin receptors and their use as medicaments
ActiveUS8791076B2Avoid damageAvoid deathOrganic active ingredientsPowder deliveryNeurotrophin Receptor p75Medicine
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS CSIC UNDIVIDED 20 INTEREST +1
Application of naringin in promoting proliferation and differentiation of neural stem cell
ActiveCN103060271BKeep proliferatingContribute to further developmentOrganic active ingredientsNervous disorderNaringinEfficacy
Owner:北京清美联创干细胞科技有限公司
Crystalline forms of neurotrophin mimetic compounds and their salts
Owner:PHARMATROPHIX
Crystalline forms of neurotrophin mimetic compounds and their salts
Owner:PHARMATROPHIX
Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases
Owner:ALZECURE PHARMA AB
Construction of controlled-release TrkC receptor ligand gelatin sponge cylinder bracket for repairing spinal cord injury
The invention relates to a construction method of a controlled-release TrkC receptor ligand-NT-3 (neurotrophin-3) gelatin sponge cylinder bracket for repairing the spinal cord injury, particularly to a construction method of a controlled-release TrkC receptor ligand gelatin sponge bracket material containing overexpression TrkC receptor cells. During application, the controlled-release TrkC receptor ligand gelatin sponge cylinder bracket with the overexpression TrkC receptor cells and differentiated cells of the overexpression TrkC receptor cells implanted is transplanted to a cross-sectional spinal cord injury position and can better promote regeneration and function repair of injured nervous centralis. The construction method has great significance in enhancement of protection of injured nerve cells after the cross-sectional spinal cord injury at the biological tissue engineering level, promotion of axonal regeneration of the nerve cells, improvement on the quality of life of the sick and the injured, reduction of social and family burdens and promotion of social and economic development in China.
Owner:SUN YAT SEN UNIV
Methods of treating amyotrophic lateral sclerosis by HGF
The invention presents a therapeutic agent (and progress suppressant) for amyotrophic lateral sclerosis (ALS) containing HGF and / or HGF gene as active ingredient. HGF has an effect of improving the motor function of ALS and life span through two actions, that is, direct neuronutrient factor activity on motoneurons, and indirect improving action of glutamate cytotoxicity on motoneurons by maintaining the level of glutamate transporter in astrocytes. Hence, HGF and / or HGF gene can be used as an effective therapeutic agent not known in the past.
Owner:NAKAMURA TOSHIKAZU
Method for preparing tissue engineering spinal cord by using ancestral cells originated from skin
ActiveCN103396984APromote proliferationArtificial cell constructsVertebrate cellsNeuregulinNeurotrophin-3
The invention discloses a method for preparing a tissue engineering spinal cord by using ancestral cells originated from skin. The method comprises the following steps: 1) separating SKPs, and passing to obtain SKPs primary cells; 2) immigrating the SKPs primary cells separated to an amplification culture medium for amplification; and 3) preparing the tissue engineering spinal cord, and dropwise adding saturated aqueous liquor of a tissue engineering spinal cord material to physiological saline liquor containing Neurotrophin-3(NT3), retinoic acid and Neuregulin; infecting the amplified SKPs by a brain-derived neurenergen adenovirus expression vector, and inoculating the cells to the tissue engineering spinal cord material to cultivate. In the method disclosed by the invention, the tissue engineering spinal cord can effectively promote cell proliferation, and the differentiating proportions of the tissue engineering spinal cord toward nerve cells and oligodendroglia cells are about 4.8% and 1.5% which are far greater than 1.8% and 0.5% of a pure support material.
Owner:ARMY MEDICAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com